Regulus Therapeutics Company Profile (NASDAQ:RGLS)

About Regulus Therapeutics

Regulus Therapeutics logoRegulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: RGLS
  • CUSIP: 75915K10
Key Metrics:
  • Previous Close: $2.74
  • 50 Day Moving Average: $3.24
  • 200 Day Moving Average: $4.49
  • 52-Week Range: $2.44 - $10.60
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.91
  • P/E Growth: -0.06
  • Market Cap: $150.01M
  • Outstanding Shares: 52,820,000
  • Beta: 1.94
  • Net Margins: -456.47%
  • Return on Equity: -56.13%
  • Return on Assets: -46.09%
  • Debt-to-Equity Ratio: 0.22%
  • Current Ratio: 10.48%
  • Quick Ratio: 10.48%
Additional Links:
Companies Related to Regulus Therapeutics:

Analyst Ratings

Consensus Ratings for Regulus Therapeutics (NASDAQ:RGLS) (?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $10.00 (252.11% upside)

Analysts' Ratings History for Regulus Therapeutics (NASDAQ:RGLS)
DateFirmActionRatingPrice TargetDetails
8/4/2016Needham & Company LLCReiterated RatingBuy$10.00View Rating Details
8/3/2016WedbushReiterated RatingOutperform$15.00View Rating Details
7/31/2016Wells Fargo & Co.Reiterated RatingOutperformView Rating Details
7/25/2016Chardan CapitalLower Price TargetBuy$14.50 -> $12.00View Rating Details
6/28/2016FBR & CoReiterated RatingOutperform$30.00 -> $9.00View Rating Details
6/28/2016BMO Capital MarketsDowngradeOutperform -> Market Perform$16.00 -> $4.00View Rating Details
6/8/2016Cowen and CompanyReiterated RatingBuyView Rating Details
6/8/2015GuggenheimInitiated CoverageBuy$16.00View Rating Details
6/2/2015Deutsche Bank AGSet Price TargetBuy$27.00View Rating Details
(Data available from 10/22/2014 forward)


Earnings History for Regulus Therapeutics (NASDAQ:RGLS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2016Q216($0.38)($0.40)$2.49 millionViewListenView Earnings Details
5/2/2016Q1($0.33)($0.40)ViewListenView Earnings Details
2/22/2016Q415($0.25)($0.14)$5.09 million$10.90 millionViewListenView Earnings Details
11/5/2015Q315($0.37)($0.25)$2.85 millionViewN/AView Earnings Details
8/4/2015Q215($0.29)($0.41)$2.40 million$3.80 millionViewN/AView Earnings Details
5/7/2015($0.26)($0.25)ViewListenView Earnings Details
2/18/2015($0.21)($0.47)ViewListenView Earnings Details
11/5/2014($0.23)($0.23)ViewListenView Earnings Details
8/6/2014Q214($0.19)($0.29)$3.19 millionViewN/AView Earnings Details
5/8/2014($0.14)($0.30)ViewN/AView Earnings Details
2/27/2014($0.13)($0.11)ViewN/AView Earnings Details
8/13/20132Q13($0.14)($0.20)$3.44 million$4.80 millionViewN/AView Earnings Details
2/20/2013Q412($0.08)($0.22)$3.50 million$3.24 millionViewN/AView Earnings Details
11/19/2012Q312($15.98)$3.81 million$2.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Regulus Therapeutics (NASDAQ:RGLS)
Current Year EPS Consensus Estimate: $-1.55 EPS
Next Year EPS Consensus Estimate: $-1.49 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.33)($0.32)($0.33)
Q2 20162($0.42)($0.32)($0.37)
Q3 20162($0.44)($0.36)($0.40)
Q4 20162($0.45)($0.35)($0.40)
Q1 20171($0.35)($0.35)($0.35)
Q2 20171($0.35)($0.35)($0.35)
Q3 20171($0.35)($0.35)($0.35)
Q4 20171($0.35)($0.35)($0.35)
(Data provided by Zacks Investment Research)


Dividend History for Regulus Therapeutics (NASDAQ:RGLS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Regulus Therapeutics (NASDAQ:RGLS)
Insider Ownership Percentage: 2.30%
Institutional Ownership Percentage: 51.46%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/3/2016Joseph P HaganCOOBuy10,000$7.19$71,900.00View SEC Filing  
2/23/2016Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,000,000$7.18$7,180,000.00View SEC Filing  
7/21/2015William H RastetterDirectorBuy100,000$10.17$1,017,000.00View SEC Filing  
7/20/2015William H RastetterDirectorBuy38,765$10.13$392,689.45View SEC Filing  
7/17/2015Isis Pharmaceuticals IncMajor ShareholderSell343,133$10.60$3,637,209.80View SEC Filing  
4/21/2015Kleanthis G XanthopoulosCEOSell200,000$17.15$3,430,000.00View SEC Filing  
4/13/2015Bruce L A CarterDirectorSell20,000$17.66$353,200.00View SEC Filing  
3/5/2015Kleanthis G XanthopoulosCEOSell89,230$20.26$1,807,799.80View SEC Filing  
2/2/2015Kleanthis G XanthopoulosCEOSell5,700$19.61$111,777.00View SEC Filing  
1/29/2015Kleanthis G XanthopoulosCEOSell145,000$18.06$2,618,700.00View SEC Filing  
1/28/2015Neil W GibsonInsiderSell80,000$18.05$1,444,000.00View SEC Filing  
11/28/2014Neil W GibsonInsiderSell2,500$19.30$48,250.00View SEC Filing  
11/3/2014Isis Pharmaceuticals IncMajor ShareholderSell1,279,411$15.94$20,393,811.34View SEC Filing  
10/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell113,084$14.02$1,585,437.68View SEC Filing  
10/22/2014Neil W GibsonInsiderSell3,300$14.44$47,652.00View SEC Filing  
10/10/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,000$6.41$12,820.00View SEC Filing  
10/10/2014Isis Pharmaceuticals IncDirectorSell10,050$6.56$65,928.00View SEC Filing  
10/9/2014Isis Pharmaceuticals IncDirectorSell4,750$6.58$31,255.00View SEC Filing  
10/8/2014Isis Pharmaceuticals IncDirectorSell3,300$6.63$21,879.00View SEC Filing  
10/3/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell10,300$6.74$69,422.00View SEC Filing  
10/3/2014Isis Pharmaceuticals IncDirectorSell3,300$6.88$22,704.00View SEC Filing  
10/2/2014Isis Pharmaceuticals IncDirectorSell3,750$6.64$24,900.00View SEC Filing  
10/1/2014Isis Pharmaceuticals IncDirectorSell3,250$6.71$21,807.50View SEC Filing  
9/30/2014Kleanthis G XanthopoulosCEOSell2,300$7.02$16,146.00View SEC Filing  
9/26/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.04$17,600.00View SEC Filing  
9/26/2014Isis Pharmaceuticals IncDirectorSell8,750$7.13$62,387.50View SEC Filing  
9/25/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.12$17,800.00View SEC Filing  
9/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,750$7.19$26,962.50View SEC Filing  
9/19/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell7,700$7.31$56,287.00View SEC Filing  
9/19/2014Isis Pharmaceuticals IncDirectorSell4,100$7.22$29,602.00View SEC Filing  
9/18/2014Isis Pharmaceuticals IncDirectorSell1,500$7.40$11,100.00View SEC Filing  
9/17/2014Isis Pharmaceuticals IncDirectorSell2,100$7.43$15,603.00View SEC Filing  
9/12/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell8,900$7.85$69,865.00View SEC Filing  
9/12/2014Isis Pharmaceuticals IncDirectorSell3,500$7.96$27,860.00View SEC Filing  
9/12/2014Neil W GibsonInsiderSell4,200$8.01$33,642.00View SEC Filing  
9/11/2014Isis Pharmaceuticals IncDirectorSell3,400$7.83$26,622.00View SEC Filing  
9/10/2014Isis Pharmaceuticals IncDirectorSell2,000$7.70$15,400.00View SEC Filing  
9/5/2014Isis Pharmaceuticals IncDirectorSell10,050$7.07$71,053.50View SEC Filing  
8/29/2014Isis Pharmaceuticals IncDirectorSell1,500$6.84$10,260.00View SEC Filing  
8/28/2014Isis Pharmaceuticals IncDirectorSell2,000$6.96$13,920.00View SEC Filing  
8/28/2014Kleanthis G XanthopoulosCEOSell3,505$7.06$24,745.30View SEC Filing  
8/27/2014Isis Pharmaceuticals IncDirectorSell1,500$7.21$10,815.00View SEC Filing  
8/22/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell5,250$6.75$35,437.50View SEC Filing  
8/21/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$6.89$17,225.00View SEC Filing  
8/20/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,000$7.14$21,420.00View SEC Filing  
8/15/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,450$6.98$10,121.00View SEC Filing  
8/14/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,750$7.04$12,320.00View SEC Filing  
8/13/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,250$7.02$15,795.00View SEC Filing  
8/8/2014Isis Pharmaceuticals IncDirectorSell1,850$6.80$12,580.00View SEC Filing  
8/7/2014Isis Pharmaceuticals IncDirectorSell2,600$6.66$17,316.00View SEC Filing  
8/6/2014Isis Pharmaceuticals IncDirectorSell3,150$7.08$22,302.00View SEC Filing  
8/1/2014Isis Pharmaceuticals IncDirectorSell2,600$6.21$16,146.00View SEC Filing  
7/31/2014Isis Pharmaceuticals IncDirectorSell1,750$6.42$11,235.00View SEC Filing  
7/30/2014Isis Pharmaceuticals IncDirectorSell1,000$6.60$6,600.00View SEC Filing  
7/25/2014Isis Pharmaceuticals IncDirectorSell1,700$6.55$11,135.00View SEC Filing  
7/24/2014Isis Pharmaceuticals IncDirectorSell1,850$6.81$12,598.50View SEC Filing  
7/23/2014Isis Pharmaceuticals IncDirectorSell1,700$6.88$11,696.00View SEC Filing  
7/18/2014Isis Pharmaceuticals IncDirectorSell5,000$6.80$34,000.00View SEC Filing  
7/17/2014Isis Pharmaceuticals IncDirectorSell5,000$6.58$32,900.00View SEC Filing  
7/16/2014Isis Pharmaceuticals IncDirectorSell3,500$6.59$23,065.00View SEC Filing  
7/11/2014Isis Pharmaceuticals IncDirectorSell1,750$6.48$11,340.00View SEC Filing  
7/10/2014Isis Pharmaceuticals IncDirectorSell4,500$6.69$30,105.00View SEC Filing  
7/9/2014Isis Pharmaceuticals IncDirectorSell1,800$7.08$12,744.00View SEC Filing  
2/4/2014Sanofimajor shareholderBuy1,303,780$7.67$9,999,992.60View SEC Filing  
1/21/2014Neil GibsonInsiderSell4,421$8.09$35,765.89View SEC Filing  
1/17/2014Neil GibsonInsiderSell4,479$8.15$36,503.85View SEC Filing  
1/16/2014Neil GibsonInsiderSell1,100$8.03$8,833.00View SEC Filing  
1/2/2014Kleanthis XanthopoulosCEOSell3,505$7.25$25,411.25View SEC Filing  
10/10/2012Stanley T CrookeDirectorBuy750,000$4.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Regulus Therapeutics (NASDAQ:RGLS)
News IconKeen Penny Stock in the News: Putting the Microscope on Regulus Therapeutics Inc. (NASDAQ:RGLS) - Duncan Research (NASDAQ:RGLS) - October 22 at 11:02 AM
News IconStock Perspective: Regulus Therapeutics Inc. (NASDAQ:RGLS) Earnings in View - CSZ News (NASDAQ:RGLS) - October 19 at 3:39 PM
News IconShare Value Diminishing Over Past Month: Regulus Therapeutics Inc. (NASDAQ:RGLS) - CSZ News (NASDAQ:RGLS) - October 15 at 6:38 PM
News IconAlps Advisors Inc. Acquires 14873 Shares of Regulus Therapeutics Inc. (RGLS) - DailyQuint (NASDAQ:RGLS) - October 15 at 6:38 PM
News IconRegulus Therapeutics Inc. (RGLS) – Broker Update - NewsDen (NASDAQ:RGLS) - October 15 at 11:47 AM
News IconLatest Analyst Ratings For Regulus Therapeutics Inc. (RGLS) - The De Soto Edge (NASDAQ:RGLS) - October 12 at 12:29 PM
News IconEarnings According to Analysts for Regulus Therapeutics Inc. (NASDAQ:RGLS)? - CSZ News (NASDAQ:RGLS) - October 10 at 11:48 AM
News IconRegulus Therapeutics Inc. (RGLS) Latest Broker Views - NewsDen - NewsDen (NASDAQ:RGLS) - October 10 at 11:48 AM logoRegulus Appoints Timothy M. Wright, M.D. as Chief Research and Development Officer (NASDAQ:RGLS) - October 7 at 12:14 PM logoRegulus Therapeutics appoints R&D officer (NASDAQ:RGLS) - October 7 at 12:14 PM logoRegulus Therapeutics Inc. (NASDAQ:RGLS) Sell Recommendations At 0 - Investor Newswire (NASDAQ:RGLS) - October 6 at 6:47 PM logoRegulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (NASDAQ:RGLS) - October 6 at 6:47 PM logoRegulus Therapeutics (RGLS) Names Timothy Wright Chief Research and Development Officer - (NASDAQ:RGLS) - October 5 at 12:20 PM logoETF’s with exposure to Regulus Therapeutics, Inc. : October 4, 2016 (NASDAQ:RGLS) - October 4 at 11:46 AM
News Icon3 Battered Biotechs That Could Turn Things Around (NASDAQ:RGLS) - October 1 at 8:32 AM
News IconNew Analyst Ratings On Regulus Therapeutics Inc. (RGLS) - NewsDen (NASDAQ:RGLS) - September 28 at 12:15 PM
News IconConsensus Take: Regulus Therapeutics Inc. (NASDAQ:RGLS) Earnings & Ratings Watch - Frisco Fastball (NASDAQ:RGLS) - September 25 at 6:14 PM
News IconWhat are Analysts Expecting for Regulus Therapeutics Inc. (NASDAQ:RGLS) Earnings? - Frisco Fastball (NASDAQ:RGLS) - September 23 at 11:45 AM logoCan Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock Hit Price Target Of $15? - Investor Newswire (NASDAQ:RGLS) - September 20 at 12:18 PM
News IconRegulus Therapeutics Inc (RGLS) Rating Reiterated by FBR & Co. - DailyQuint (NASDAQ:RGLS) - September 19 at 11:36 AM logoRegulus Therapeutics Inc. (NASDAQ:RGLS) Is Expected To Post ... - (NASDAQ:RGLS) - September 18 at 11:15 AM
News IconWhat are Research Firms Saying About Regulus Therapeutics Inc. (NASDAQ:RGLS)? - Frisco Fastball (NASDAQ:RGLS) - September 14 at 11:25 AM
News IconRegulus Therapeutics Inc (RGLS), Sophiris Bio Inc (SPHS) | Share ... - share market updates (press release) (NASDAQ:RGLS) - September 9 at 11:48 AM
News IconPlacing Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Under the Microscope - Post News (NASDAQ:RGLS) - September 8 at 10:51 AM
News IconHC Stocks in the Rumor= Pernix Therapeutics Holdings Inc (PTX), Regulus Therapeutics Inc (NASDAQ:RGLS) - share market updates (press release) (NASDAQ:RGLS) - September 8 at 10:51 AM logoHow These Biotech Stocks are Faring? -- Immunomedics, Sequenom, INSYS Therapeutics, and Regulus Therapeutics - PR Newswire (press release) (NASDAQ:RGLS) - September 8 at 10:51 AM logoETF’s with exposure to Regulus Therapeutics, Inc. : September 7, 2016 (NASDAQ:RGLS) - September 7 at 7:09 PM
News IconStock Struggling for the Quarter: Regulus Therapeutics Inc. (NASDAQ:RGLS) - Post News (NASDAQ:RGLS) - September 4 at 11:02 AM logoRegulus Therapeutics Inc. (NASDAQ:RGLS) Is Expected To Post EPS Of $-0.36 - (NASDAQ:RGLS) - September 3 at 6:12 PM logoRegulus to Present at the 2016 Wells Fargo Healthcare Conference (NASDAQ:RGLS) - August 31 at 12:15 PM logoCan Regulus Therapeutics Inc. (NASDAQ:RGLS) Meet Analysts Expectations? - Stocks Daily (NASDAQ:RGLS) - August 22 at 11:43 AM logoWill Regulus Therapeutics Inc. (NASDAQ:RGLS) Hit $15 Price Target? - Investor Newswire (NASDAQ:RGLS) - August 18 at 7:24 PM logoWill Regulus Therapeutics Inc. (NASDAQ:RGLS) Surprise Analysts? - Investor Newswire (NASDAQ:RGLS) - August 14 at 11:33 AM logoREGULUS THERAPEUTICS INC. Financials (NASDAQ:RGLS) - August 10 at 7:38 PM logoRegulus Therapeutics Inc.: Regulus to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:RGLS) - August 9 at 7:24 PM logoRegulus to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:RGLS) - August 9 at 7:24 PM logoETF’s with exposure to Regulus Therapeutics, Inc. : August 8, 2016 (NASDAQ:RGLS) - August 8 at 7:20 PM logoRegulus Therapeutics, Inc. :RGLS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 (NASDAQ:RGLS) - August 5 at 7:21 PM logoRegulus Therapeutics Inc. (RGLS) Jumps 6.8% on August 03 - (NASDAQ:RGLS) - August 5 at 10:07 AM
News IconHC Stocks in Actions: Pernix Therapeutics Holdings Inc (NASDAQ:PTX), Regulus Therapeutics Inc (NASDAQ:RGLS) - share market updates (press release) (NASDAQ:RGLS) - August 4 at 7:36 PM logoStrong Sell Calls For Regulus Therapeutics Inc. (NASDAQ:RGLS) At 0 - Investor Newswire (NASDAQ:RGLS) - August 4 at 7:36 PM logoEdited Transcript of RGLS earnings conference call or presentation 2-Aug-16 9:00pm GMT (NASDAQ:RGLS) - August 3 at 10:23 AM logoREGULUS THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:RGLS) - August 3 at 10:23 AM logoRegulus Reports Second Quarter 2016 Financial Results (NASDAQ:RGLS) - August 2 at 7:27 PM logoRegulus reports 2Q loss (NASDAQ:RGLS) - August 2 at 7:27 PM logoQ2 2016 Regulus Therapeutics Inc Earnings Release - After Market Close (NASDAQ:RGLS) - August 2 at 12:04 PM logoRegulus Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today (NASDAQ:RGLS) - August 2 at 12:04 PM logoMarket Update – Biggest Movers Pre Market (NASDAQ:RGLS) - August 1 at 11:47 AM logoRegulus Therapeutics Inc. (RGLS) Drops 13.05% on July 28 - (NASDAQ:RGLS) - July 31 at 11:02 AM
News IconAnalyst Recommended Stock: Anavex Life Sciences Corp. (AVXL) (NASDAQ:RGLS) - July 29 at 7:18 PM


Regulus Therapeutics (NASDAQ:RGLS) Chart for Saturday, October, 22, 2016

Last Updated on 10/22/2016 by Staff